Statins for the primary prevention of cardiovascular disease - PubMed (original) (raw)

Review

Statins for the primary prevention of cardiovascular disease

Fiona Taylor et al. Cochrane Database Syst Rev. 2011.

Update in

Abstract

Background: Reducing high blood cholesterol, a risk factor for cardiovascular disease (CVD) events in people with and without a past history of coronary heart disease (CHD) is an important goal of pharmacotherapy. Statins are the first-choice agents. Previous reviews of the effects of statins have highlighted their benefits in people with coronary artery disease. The case for primary prevention, however, is less clear.

Objectives: To assess the effects, both harms and benefits, of statins in people with no history of CVD.

Search strategy: To avoid duplication of effort, we checked reference lists of previous systematic reviews. We searched the Cochrane Central Register of Controlled Trials (Issue 1, 2007), MEDLINE (2001 to March 2007) and EMBASE (2003 to March 2007). There were no language restrictions.

Selection criteria: Randomised controlled trials of statins with minimum duration of one year and follow-up of six months, in adults with no restrictions on their total low density lipoprotein (LDL) or high density lipoprotein (HDL) cholesterol levels, and where 10% or less had a history of CVD, were included.

Data collection and analysis: Two authors independently selected studies for inclusion and extracted data. Outcomes included all cause mortality, fatal and non-fatal CHD, CVD and stroke events, combined endpoints (fatal and non-fatal CHD, CVD and stroke events), change in blood total cholesterol concentration, revascularisation, adverse events, quality of life and costs. Relative risk (RR) was calculated for dichotomous data, and for continuous data pooled weighted mean differences (with 95% confidence intervals) were calculated.

Main results: Fourteen randomised control trials (16 trial arms; 34,272 participants) were included. Eleven trials recruited patients with specific conditions (raised lipids, diabetes, hypertension, microalbuminuria). All-cause mortality was reduced by statins (RR 0.83, 95% CI 0.73 to 0.95) as was combined fatal and non-fatal CVD endpoints (RR 0.70, 95% CI 0.61 to 0.79). Benefits were also seen in the reduction of revascularisation rates (RR 0.66, 95% CI 0.53 to 0.83). Total cholesterol and LDL cholesterol were reduced in all trials but there was evidence of heterogeneity of effects. There was no clear evidence of any significant harm caused by statin prescription or of effects on patient quality of life.

Authors' conclusions: Although reductions in all-cause mortality, composite endpoints and revascularisations were found with no excess of adverse events, there was evidence of selective reporting of outcomes, failure to report adverse events and inclusion of people with cardiovascular disease. Only limited evidence showed that primary prevention with statins may be cost effective and improve patient quality of life. Caution should be taken in prescribing statins for primary prevention among people at low cardiovascular risk.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Methodological quality summary: review authors’ judgements about each methodological quality item for each included study.

Figure 2

Figure 2

Methodological quality graph: review authors’ judgements about each methodological quality item presented as percentages across all included studies.

Figure 3

Figure 3

Funnel plot of comparison: 2 Mortality and Morbidity, outcome: 2.1 Total Mortality.

Comment in

Similar articles

Cited by

References

References to studies included in this review

    1. Furberg C, Adams H, Appelgate W, et al. for the Asymptomatic Caritid Artery Progression Study (ACAPS) Research Group Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation. 1994;90:1679–87. - PubMed
    1. *
    2. Brookes L, Nakamura H. MEGA: Management of elevated cholesterol in the primary prevention group of adult Japanese. American Heart Association 2005 Scientific Sessions. 2008.
    3. Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study Group Design and baseline characteristics of a study of primary prevention of coronary events with pravastatin among Japanese with mildly elevated cholesterol levels. Circulation Journal. 2004:860–7. - PubMed
    4. Nakamura H. The design and background characteristics of the study on the primary prevention of coronary events with pravastatin among Japanese with mildly elevated cholesterol levels (Japanese Mega Study) Atherosclerosis. 2000;151(1):136.
    1. *
    2. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. Journal of the American Medical Association. 1998;279(20):1615–22. - PubMed
    3. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. New England Journal of Medicine. 2001;344(26):1959–65. - PubMed
    1. Knopp RH, D’Emden M, Smilde JG, Pocock SJ, on behalf of the ASPEN Study Group Efficacy and Safety of Atorvastatin in the Prevention of Cardiovascular End Points in Subjects With Type 2 Diabetes. The Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN) Diabetes Care. 2006;29(7):1478–85. - PubMed
    1. Baldassarre D, Veglia F, Gobbi C, Gallus G, Ventura A, Crepaldi G, et al. Intima-media thickness after pravastatin stabilizes also in patients with moderate to no reduction in LDL-cholesterol levels: the carotid atherosclerosis Italian ultrasound study. Atherosclerosis. 2000;151:575–83. - PubMed
    2. *
    3. Mercuri M, Bond G, Sirtori CR, Veglia F, Crepaldi G, Feruglio S, et al. Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic Mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study. American Journal of Medicine. 1996;101:627–34. - PubMed
    4. Sirtori CR, Bianchi G, Bond MG, D’Alo G, Gallus G, Liberatore S, et al. Pravastatin intervention trial on carotid artery atherosclerosis in patients with mild hypercholesterolemia: the CAIUS Study. International Journal of Cardiac Imaging. 1995;11(Suppl 2):119–24.

References to studies excluded from this review

    1. The Anti-hypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT) Major outcomes in moderately hypercholesterolemic, hypertensive patients randomised to pravastatin versus usual care. JAMA. 2002;288:2998–3007. - PubMed
    1. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and anti-oxidant therapy on endothelium-dependent coronary vasomotion. New England Journal of Medicine. 1993;332:488–93. - PubMed
    1. O’Brien E. Anglo-Scandinavian Cardiac Outcomes Trial ASCOT. Main protocol summary & sub-study protocols. Journal of Human Hypertension. 2001;15(Suppl 1):S1–S96. - PubMed
    2. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. The Lancet. 2003;361:1149–58. - PubMed
    3. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cariac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Zeitschrift für Kardiologie. 2003;92:613. - PubMed
    4. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. Journal of Hypertension. 2001;19:1139–1147. - PubMed
    5. Svilaas A, Kjeldsen S, Midtbo K, Westheim A, Syvertsen JO. Statin therapy for hypertensive patients [Statinbehandling av blodtrykkspasienter] Tidsskrift for Den Norske Laegeforening. 2004;124:165–6. - PubMed
    1. Bak AA, Huizer J, Leijten PA, Rila H, Grobbee DE. Diet and pravastatin in moderate hypercholesterolaemia: a randomized trial in 215 middle-aged men free from cardiovascular disease. Journal of Internal Medicine. 1998;244(5):371–8. - PubMed
    1. Hedblad B, Wikstand J, Janzon L, Wedel H, Berglund G. Low dose metaprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study. Circulation. 2001;103:1721–6. - PubMed

References to studies awaiting assessment

    1. Ridker PM, Danielson E, Francisco MIA, Fonseca AH, Genest J, Gotto Jnr AM, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. New England Journal of Medicine. 2008;359(21):2195–207. - PubMed

Additional references

    1. Abramson J, Wright JM. Are lipid-lowering guidelines evidence-based? Lancet. 2007;369:168–9. - PubMed
    1. Als-Nielsen B, Chen W, Gluud C, Kjaergard LL. Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events? JAMA. 2003;290(7):921–8. - PubMed
    1. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. The Lancet. 2005;366(9493):1267–78. - PubMed
    1. Bartlett C, Davey P, Dieppe P, Doyal L, Ebrahim S, Egger M. Women, older persons, and ethnic minorities: factors associated with their inclusion in randomised controlled trials of statins 1990 to 2001. Heart. 2003;89:327–8. - PMC - PubMed
    1. Bartlett C, Doyal L, Ebrahim S, Davey P, Bachmann M, Egger M, et al. The causes and effects of socio-demographic exclusions from clinical trials. Health Technology Assessment. 2005;9(38):1–152. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources